CLAIMS

What is claimed is:

1. An HPV immunogenic composition for use in preventing HPV-related diseases or infections, comprising:

chimeric HPV L1 protein of HPV types 6, 11, 16, 18, 31, 35, 39, 45, 51, 52, 56 and 58, HPV Type 33 L1 protein and HPV Type 59 L1 protein,

wherein said chimeric HPV L1 protein of HPV Types 6, 11, 16, 18, 31, 35, 39, 45, 51, 52, 56 and 58 is shown in SEQ ID No: 3, SEQ ID No: 16, SEQ ID No: 29, SEQ ID No: 42, SEQ ID No: 55, SEQ ID No: 71, SEQ ID No: 84, SEQ ID No: 97, SEQ ID No: 110, SEQ ID No: 123, SEQ ID No: 136 and SEQ ID No: 149, respectively, and

the HPV Type 33 L1 protein and HPV Type 59 L1 protein is shown in SEQ ID No: 66 and SEQ ID No: 160, respectively.

2. The HPV immunogenic composition according to claim 1,

wherein said chimeric HPV L1 protein of HPV Types 6 is encoded by SEQ ID No: 4,

wherein said chimeric HPV L1 protein of HPV Types 11 is encoded by SEQ ID No: 17,

wherein said chimeric HPV L1 protein of HPV Types 16 is encoded by SEQ ID No: 30,

wherein said chimeric HPV L1 protein of HPV Types 18 is encoded by SEQ ID No: 43,

wherein said chimeric HPV L1 protein of HPV Types 31 is encoded by SEQ ID No: 56,

wherein said chimeric HPV L1 protein of HPV Types 35 is encoded

by SEQ ID No: 72,

wherein said chimeric HPV L1 protein of HPV Types 39 is encoded by SEQ ID No: 85,

wherein said chimeric HPV L1 protein of HPV Types 45 is encoded by SEQ ID No: 98,

wherein said chimeric HPV L1 protein of HPV Types 51 is encoded by SEQ ID No: 111,

wherein said chimeric HPV L1 protein of HPV Types 52 is encoded by SEQ ID No: 124,

wherein said chimeric HPV L1 protein of HPV Types 56 is encoded by SEQ ID No: 137, or

wherein said chimeric HPV L1 protein of HPV Types 58 is encoded by SEQ ID No: 150;

wherein said HPV L1 protein of HPV Types 33 is encoded by SEQ ID No: 67; or

wherein said HPV L1 protein of HPV Types 59 is encoded by SEQ ID No: 161.

3. The HPV immunogenic composition according to any one of claims 1-2, wherein said HPV immunogenic composition further comprises a physiologically acceptable carrier and, optionally, an adjuvant.

4. The HPV immunogenic composition according to claim 3, wherein said adjuvant is an aluminum phosphate adjuvant.

5. Use of the HPV immunogenic composition of any one of claims 1-4 in the preparation of vaccines or drugs for preventing HPV-

related diseases or infections.